Valuation: Apogee Therapeutics, Inc.

Market Cap 10.02B 8.76B 8.08B 7.46B 14.16B 955B 14.4B 96.56B 37.92B 471B 37.61B 36.79B 1,618B P/E 2026 *
-31x
P/E 2027 * -23.9x
Enterprise Value 9.04B 7.9B 7.29B 6.73B 12.78B 862B 12.99B 87.12B 34.21B 425B 33.93B 33.19B 1,460B EV / Sales 2026 *
994x
EV / Sales 2027 * 742x
Free-Float
90.89%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Apogee Therapeutics, Inc.

1 day+0.06%
1 week+0.56%
Current month+0.69%
1 month+61.57%
3 months+54.92%
6 months+71.37%
Current year+77.07%
1 week 133.13
Extreme 133.13
133.87
1 month 84.01
Extreme 84.01
133.87
Current year 60.35
Extreme 60.35
133.87
1 year 34.34
Extreme 34.34
133.87
3 years 14.19
Extreme 14.19
133.87
5 years 14.19
Extreme 14.19
133.87
10 years 14.19
Extreme 14.19
133.87
Manager TitleAgeSince
Chief Executive Officer 36 31/08/2022
Director of Finance/CFO 60 31/12/2022
Chief Tech/Sci/R&D Officer - 30/04/2023
Director TitleAgeSince
Director/Board Member 54 21/06/2023
Director/Board Member 62 31/05/2023
Director/Board Member 36 31/05/2023
Date Insider Type Main position Quantity % Market Cap.
06-30Fiscal year

Chief Technology Officer

13,750 0.0246%
06-21Sell

Chief Executive Officer

-80,000 0.1429%
06-21Sell

Chief Technology Officer

-26,400 0.0471%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%+0.56%+246.51% - 10.02B
+0.58%+2.06%+2.92%+10.86% 50.73B
-2.22%-1.25%+385.40%+586.81% 39.73B
-0.54%+0.39%+25.57%-5.28% 34.69B
-1.36%+0.35%+17.88%+55.14% 33.21B
+1.21%-4.58%+3.00%+35.46% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+63.97%+122.60% 15.37B
+0.23%-0.58%+13.76%+21.11% 13.78B
-0.62%-3.09%+10.29%-31.35% 12.85B
Average -0.40%-0.69%+85.48%+99.42% 25.39B
Weighted average by Cap. -0.46%-0.20%+87.70%+124.32%

Financials

2026 *2027 *
Net sales 9.09M 7.95M 7.33M 6.77M 12.85M 867M 13.07M 87.64M 34.41M 427M 34.13M 33.39M 1.47B 12.5M 10.93M 10.08M 9.31M 17.67M 1.19B 17.97M 120M 47.32M 587M 46.93M 45.91M 2.02B
Net income -318M -278M -256M -237M -449M -30.28B -457M -3.06B -1.2B -14.92B -1.19B -1.17B -51.29B -416M -364M -336M -310M -589M -39.72B -599M -4.01B -1.58B -19.57B -1.56B -1.53B -67.26B
Net Debt -980M -857M -790M -730M -1.38B -93.42B -1.41B -9.44B -3.71B -46.02B -3.68B -3.6B -158B -740M -647M -597M -552M -1.05B -70.6B -1.06B -7.14B -2.8B -34.78B -2.78B -2.72B -120B
Logo Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Date Price Change Volume
10/07/26 US$133.65 +0.06% 787,824
09/07/26 US$133.57 +0.24% 2,057,373
08/07/26 US$133.25 -0.22% 2,543,882
07/07/26 US$133.54 +0.03% 1,054,061
06/07/26 US$133.50 +0.44% 1,595,460
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
133.65USD
Average target price
130.53USD
Spread / Average Target
-2.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APGE Stock